From: Safety of inactivated SARS-CoV-2 vaccines in patients with allergic diseases
After first dose | After second dose | |||||
---|---|---|---|---|---|---|
AD (n = 381) | CG (n = 1545) | P value | AD (n = 381) | CG (n = 1545) | P value | |
No symptoms | 181 (47,5) | 968 (62.7) | < 0.001 | 232 (60.9) | 1166 (75.5) | < 0.001 |
Local reaction | 124 (32.5) | 309 (20.0) | < 0.001 | 106 (27.8) | 253 (16.4) | < 0.001 |
Pain | 118 (31.0) | 292 (18.9) | < 0.001 | 99 (26.0) | 232 (15.0) | < 0.001 |
Redness | 3 (0.8) | 8 (0.5) | 0.806 | 4 (1.0) | 11 (0.7) | 0.729 |
Swelling | 10 (2.6) | 26 (1.7) | 0.224 | 11 (2.9) | 27 (1.7) | 0.152 |
Pruritus | 0 | 4 (0.3) | 1.000 | 0 | 3 (0.2) | 1.000 |
Malaise | 0 | 2 (0.1) | 1.000 | 0 | 1 (0.1) | 1.000 |
Systemic reactions | 115 (30.2) | 354 (22.9) | 0.003 | 65 (17.1) | 172 (11.1) | 0.002 |
Fever | 7 (1.8) | 28 (1.8) | 0.974 | 5 (1.3) | 14 (0.9) | 0.668 |
Chills | 8 (2.1) | 8 (0.5) | 0.006 | 0 (0.0) | 5 (0.3) | 0.590 |
Fatigue | 62 (16.3) | 151 (9.8) | < 0.001 | 30 (7.9) | 77 (5.0) | 0.027 |
Headache | 12 (3.1) | 17 (1.1) | 0.003 | 6 (1.6) | 5 (0.3) | 0.012 |
Vertigo | 22 (5.8) | 50 (3.2) | 0.019 | 10 (2.6) | 25 (1.6) | 0.188 |
Somnolence | 4 (1.0) | 25 (1.6) | 0.561 | 4 (1.0) | 10 (0.6) | 0.623 |
Vomiting | 6 (1.6) | 14 (0.9) | 0.249 | 1 (0.3) | 4 (0.3) | 1.000 |
Diarrhea | 12 (3.1) | 24 (1.6) | 0.039 | 3 (0.8) | 14 (0.9) | 0.933 |
Abdominal pain | 1 (0.3) | 6 (0.4) | 0.913 | 0 | 3 (0.2) | 1.000 |
Stuffy nose | 6 (1.6) | 16 (1.0) | 0.375 | 3 (0.8) | 10 (0.6) | 0.960 |
Sore throat | 11 (2.9) | 27 (1.7) | 0.152 | 7 (1.8) | 16 (1.0) | 0.197 |
Cough | 4 (1.0) | 14 (0.9) | 0.971 | 5 (1.3) | 9 (0.6) | 0.244 |
Chest pain | 0 | 1 (0.1) | 1.000 | 0 | 0 | 1.000 |
Cardiopalmus | 1 (0.3) | 3 (0.2) | 0.586 | 1 (0.3) | 3 (0.2) | 0.586 |
New or worsened muscle pain | 7 (1.8) | 15 (1.0) | 0.154 | 7 (1.8) | 13 (0.8) | 0.151 |
New or worsened joint pain | 1 (0.3) | 3 (0.2) | 0.586 | 1 (0.3) | 4 (0.3) | 1.000 |
Skin rash | 12 (3.1) | 19 (1.2) | 0.008 | 6 (1.6) | 7 (0.5) | 0.041 |